Rozpędek-Kamińska, W.; Galita, G.; Saramowicz, K.; Granek, Z.; Barczuk, J.; Siwecka, N.; Pytel, D.; Majsterek, I.
Evaluation of the LDN-0060609 PERK Inhibitor as a Selective Treatment for Primary Open-Angle Glaucoma: An In Vitro Study on Human Retinal Astrocytes. Int. J. Mol. Sci. 2024, 25, 728.
https://doi.org/10.3390/ijms25020728
AMA Style
Rozpędek-Kamińska W, Galita G, Saramowicz K, Granek Z, Barczuk J, Siwecka N, Pytel D, Majsterek I.
Evaluation of the LDN-0060609 PERK Inhibitor as a Selective Treatment for Primary Open-Angle Glaucoma: An In Vitro Study on Human Retinal Astrocytes. International Journal of Molecular Sciences. 2024; 25(2):728.
https://doi.org/10.3390/ijms25020728
Chicago/Turabian Style
Rozpędek-Kamińska, Wioletta, Grzegorz Galita, Kamil Saramowicz, Zuzanna Granek, Julia Barczuk, Natalia Siwecka, Dariusz Pytel, and Ireneusz Majsterek.
2024. "Evaluation of the LDN-0060609 PERK Inhibitor as a Selective Treatment for Primary Open-Angle Glaucoma: An In Vitro Study on Human Retinal Astrocytes" International Journal of Molecular Sciences 25, no. 2: 728.
https://doi.org/10.3390/ijms25020728
APA Style
Rozpędek-Kamińska, W., Galita, G., Saramowicz, K., Granek, Z., Barczuk, J., Siwecka, N., Pytel, D., & Majsterek, I.
(2024). Evaluation of the LDN-0060609 PERK Inhibitor as a Selective Treatment for Primary Open-Angle Glaucoma: An In Vitro Study on Human Retinal Astrocytes. International Journal of Molecular Sciences, 25(2), 728.
https://doi.org/10.3390/ijms25020728
